139 related articles for article (PubMed ID: 8619695)
1. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
[TBL] [Abstract][Full Text] [Related]
2. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
[TBL] [Abstract][Full Text] [Related]
3. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques.
Mabry CD; Thompson BW; Read RC; Campbell GS
Surgery; 1981 Nov; 90(5):889-95. PubMed ID: 7302842
[TBL] [Abstract][Full Text] [Related]
4. Safety issues in heparin and protamine administration for extracorporeal circulation.
Jobes DR
J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
[TBL] [Abstract][Full Text] [Related]
5. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy.
Feindt P; Seyfert UT; Volkmer I; Straub U; Gams E
Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949
[TBL] [Abstract][Full Text] [Related]
6. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics.
Cipolle RJ; Uden DL; Gruber SA; Jossart GH; Taylor CA; Erdmann GR; Canafax DM
Pharmacotherapy; 1990; 10(6):367-72. PubMed ID: 2287554
[TBL] [Abstract][Full Text] [Related]
8. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
10. Effects of low doses of aprotinin on clotting times activated with celite and kaolin.
Farooqi N; De Hert S; Vlaeminck R; De Bakker A; Govaerts E; Vermeyen K
Acta Anaesthesiol Belg; 1993; 44(3):87-92. PubMed ID: 7508668
[TBL] [Abstract][Full Text] [Related]
11. Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control.
Andrew M; MacIntyre B; MacMillan J; Williams WG; Gruenwald C; Johnston M; Burrows F; Wang E; Adams M
Thromb Haemost; 1993 Dec; 70(6):937-41. PubMed ID: 8165615
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
[TBL] [Abstract][Full Text] [Related]
13. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
Huyzen RJ; van Oeveren W; Wei F; Stellingwerf P; Boonstra PW; Gu YJ
Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
[TBL] [Abstract][Full Text] [Related]
14. In vitro effects of aprotinin on activated clotting time measured with different activators.
Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB
J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
[TBL] [Abstract][Full Text] [Related]
15. Aprotinin and heparin monitoring during cardiopulmonary bypass.
Hunt BJ; Segal H; Yacoub M
Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
[TBL] [Abstract][Full Text] [Related]
16. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
Pötzsch B; Madlener K; Seelig C; Riess CF; Greinacher A; Müller-Berghaus G
Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
[TBL] [Abstract][Full Text] [Related]
19. [The significance of heparin concentration measurement during cardiopulmonary bypass--effect of heparin-coated circuit during normothermic bypass].
Komiya T; Ban K; Yamazaki K; Ishii O; Nakamura T; Kanzaki Y
Nihon Kyobu Geka Gakkai Zasshi; 1997 Nov; 45(11):1810-5. PubMed ID: 9430957
[TBL] [Abstract][Full Text] [Related]
20. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Joiner-Maier D; Santoro SA; Spitznagel E; Weitz JI; Goodnough LT
Thromb Haemost; 1996 Dec; 76(6):902-8. PubMed ID: 8972009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
